Moderate to severe obstructive sleep apnea with chronic rhinitis Moderate to severe obstructive sleep apnea chronic rhinitis apnea hypopnea index intranasal steroid
Conditions
Interventions
Fluticasone furoate,
Nasal spray 27.5 mcg/1dose,
120 doses/bottle,
1C 13/51 (N) [drug'
s ID],Placebo nasal spray,
contains glucose anhydrous,
polysorbate 80,
benzalkonium chloride,
disodium edetate,
Placebo Comparator Drug,Placebo Comparator Drug
intranasal steriod,placebo
Sponsors
NONE
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. 20-65 year old volunteers 2. Polysomnography test with apnea-hypopnea index at least 15 events per hour 3. Total nasal symptom score questionnaire required more than 6 4. Skin test required 5. Modified Mallampati grade 1-2
Exclusion criteria
Exclusion criteria: 1. Without serious co-morbidity disease; resistant hypertension, poor controlled cardiovascular disease, cerebrovascular disease 2. Morbid obesity; body mass index was more than 30 kg/m2 3. Oral appliance or continue positive airway pressure previous used 4. Bi-level positive airway pressure used 5. Previous intranasal steroid used within 3 months of research period 6. Could not attend 2 appointments and poor technique of drug used 7. Could not discontinue anti-allergy drug within 7 days of before enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| apnea hypopnea index 1 month polysomnography test | — |
Secondary
| Measure | Time frame |
|---|---|
| sleep quality 1 month questionnaire | — |
Countries
thailand
Contacts
Public Contactvorakamol phoophiboon
faculty of medicine, Chulalongkorn university
Outcome results
None listed